Pfizer's ADCETRIS® Regimen Produces Clinically Meaningf

Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone, resulting in median overall survival of...

Related Keywords

Japan , United States , South Korea , Canada , American , Korea , America , Canadian , Roger Dansey , Exchange Commission , American Society Of Clinical Oncology , National Library Of Medicine , Linkedin , Youtube , Leukemia Lymphoma Society , College Of Medicine , Pfizer Inc , Catholic University Of Korea , Pfizer , Clinical Oncology , Annual Meeting , Jeunga Kim , Catholic University , Chief Development Officer , North America , Diffuse Largeb Cell Lymphoma , Prescribing Information , Pfizer Oncology , Breakthroughs That Change Patient Lives , Annual Report , Looking Information , Factors That May Affect Future , Diffuse Largeb Cell , Updated April ,